Find the latest Tempest Therapeutics, Inc. Common Stock (TPST) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq.com.
Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classitargeted and immune-mediated therapeutics to fight cancer, today announced thatCancer Research Communicationspublished positive clinical data from the dose-escalation Phase 1 trial of TPST-1120 in an article titled "...
TPST U.S.: Nasdaq Tempest Therapeutics Inc.Watchlist Alert Open Last Updated: Oct 17, 2024 10:07 a.m. EDT Real time quote $ 1.0350 -0.0750 -6.76% Previous Close $1.1100 Toggle Chart Options Advanced Charting Range Dropdown $ % Vol ...
TPST | Complete Tempest Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provi
Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.
TPSTTempest Therapeutics, Inc. Stock Price & Overview Follow 2.25K followers $0.92-0.042 (-4.44%)4:00 PM 10/31/24 NASDAQ |$USD |Pre-Market:$0.92+0.01 (+0.62%)6:39 AM Summary Ratings Financials Earnings Dividends Valuation Growth
The Investor Relations website contains information about Tempest Therapeutics's business for stockholders, potential investors, and financial analysts.
Latest Tempest Therapeutics Inc (3OS:BER) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
Tempest Therapeutics IncTPST:NASDAQ RT Quote|Last NASDAQ LS, VOL From CTA|USD After Hours:Last |7:59 PM EDT 0.99-0.1121(-10.1909%) Volume 3,109,997 Close 1.10UNCH(UNCH) Volume 3,985,792 52 week range 0.92-6.00 1D 5D 1M 3M